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Abstract: Arginine is a crucial amino acid that serves to
modulate the cellular immune response during infection.
Arginine is also a common substrate for both inducible
nitric oxide synthase (iNOS) and arginase. The generation
of nitric oxide from arginine is responsible for efficient
immune response and cytotoxicity of host cells to kill the
invading pathogens. On the other hand, the conversion of
arginine to ornithine and urea via the arginase pathway
can support the growth of bacterial and parasitic
pathogens. The competition between iNOS and arginase
for arginine can thus contribute to the outcome of several
parasitic and bacterial infections. There are two isoforms
of vertebrate arginase, both of which catalyze the
conversion of arginine to ornithine and urea, but they
differ with regard to tissue distribution and subcellular
localization. In the case of infection with Mycobacterium,
Leishmania, Trypanosoma, Helicobacter, Schistosoma, and
Salmonella spp., arginase isoforms have been shown to
modulate the pathology of infection by various means.
Despite the existence of a considerable body of evidence
about mammalian arginine metabolism and its role in
immunology, the critical choice to divert the host arginine
pool by pathogenic organisms as a survival strategy is still
a mystery in infection biology.
Introduction
Arginase, the arginine hydrolytic enzyme, was first discovered
by Kossel and Dakin in 1904 in the mammalian liver [1]. It is a
binuclear manganese metalloenzyme that catalyzes the hydrolysis
of L-arginine to urea and ornithine. There are two isoforms of the
enzyme, namely arginase I and II. Arginase I is a trimeric cytosolic
protein, total size 34,700 Da, and is expressed in erythrocytes in
humans and higher primates. The second isoform, arginase II, is
also a trimeric mitochondrial protein, total size 36,100 Da, and is
expressed in extrahepatic tissues like the small intestine, kidney,
brain, monocytes, and macrophages [2]. Arginase II is synthesized
as a pre-protein, imported to mitochondria, and processed to the
mature form [3,4]. In addition, some pathogens possess their own
arginase, which is required to produce endogenous urea [5,6].
One of the competing enzymes of arginase for L-arginine is
nitric oxide synthase (NOS). There are three types of nitric oxide
synthases, namely, inducible NOS (iNOS), neuronal NOS, and
endothelial NOS. iNOS is not constitutively expressed but highly
induced by lipopolysaccharide (LPS), lipoteichoic acid (LTA), and
Type 1 cytokines like interferon gamma (IFNc), tumour necrosis
factor alpha (TNF-a), interleukin 1 (IL-1), and IL-2. Nitric oxide
(NO) contributes to the innumerable physiological processes, the
understanding of which is relevant to fathom the pathogenesis of
infection [3,7]. NO is the central component of innate immunity
in murine macrophages and is an effective antimicrobial agent,
especially against intracellular pathogens such as Mycobacterium
tuberculosis, Leishmania major, Salmonella, and also against extracellu-
lar bacteria like Escherichia coli [8].
It has been proved that the availability of the intracellular
arginine is a rate-limiting factor in NO synthesis, although
extracellular arginine concentration has been shown to play a
more important role in regulating NO synthesis compared to
intracellular arginine [3]. Arginase and NOS use arginine as a
common substrate and compete with each other for this substrate.
Although Km of arginase is in mM range and of NOS in mM
range, arginase Vmax at body pH is 1,000 times more than that of
NOS, indicating that similar rates of substrate usage occur for both
enzymes at a low arginine concentration [3]. Interestingly, cAMP,
LPS, and Type 2 cytokines such as IL-4, IL-13, and TGF-b induce
arginase I expression in macrophages. Type 1 cytokines like IFNc
increase NO production by NOS2 induction and inhibit IL-4- and
IL-10-driven arginase I activity. The alternative activation by
Type 2 cytokines like IL-4 and IL-13 inhibits NOS2 function and
induces arginase I, leading to increased humoral immunity, tissue
repair, and allergic and anti-parasitic response [9]. In addition, the
polyamines produced in the arginase pathway downregulate pro-
inflammatory cytokine release. Arginase activation results in
collagen synthesis by proline and therefore is hypothesized to be
required in wound healing [10]. The different players and the
critical regulation of the arginase isoforms is depicted in Figure 1.
Hence, the critical interplay between arginase and NOS might
regulate the outcome of several pathologic conditions by
modulating the amount of NO produced. Furthermore, the
production of polyamines and other metabolic intermediates of the
arginase pathway could also dictate the severity of any infection.
On the other hand, the cytokine profile after any infection is a key
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determines the disease outcome. To date, sufficient evidence has
accumulated to conclude that arginase is not a mere urea cycle
enzyme; rather, it is a moonlighting enzyme that acts as a double-
edged sword in immunity. This review considers the recent studies
that deal with the modulation of expression and function of the
arginase isoforms by various successful pathogens.
Modulation of the Arginase Pathway by Various
Pathogens
Bacterial Interference of Arginase
Helicobacter pylori is a Gram-negative micro-aerophillic bacteria
that selectively colonize the human stomach. It causes chronic
gastritis, peptic ulcer, gastric carcinoma, and lymphoma, leading
to its classification as a class I carcinogen [11]. H. pylori arginase is
encoded by the gene rocF, which is constitutively expressed.
Although both the wild-type and rocF mutant stimulate similar
levels of iNOS mRNA, a significantly greater amount of NO
production is elicited by the mutant strain in RAW macrophages
at a physiologically relevant arginine concentration. This agrees
with the hampered survival of the rocF mutant strain, thus
indicating the role of the pathogen-induced arginase to quench
arginine from iNOS [12,13]. In a previous study, the Helicobacter
arginase was found to protect the bacteria from acid stress, and an
arginase-deficient strain showed attenuated colonization in the
mouse model [5]. In addition, Helicobacter arginase also impairs
host T cell function by reducing CD3f chain expression, and this
phenotype might play a very important role during Helicobacter
infection [14]. These unique functions imply that the Helicobacter
arginase has evolved to allow the bacteria to effectively compete
with its host in the mucous layer. The decrease in host NO
production by Helicobacter arginase may have two important
outcomes. The first one certainly is to avoid host nitrosative stress,
and the second one might be to reduce the NO-mediated damage
of the gastric mucosa. If the second possibility is true, then arginase
must be one of the very essential factors for the long-term survival
and proliferation of this pathogen in the gastric niche.
In addition, H. pylori upregulates the host arginase II in RAW
macrophages and in mouse and human gastritis tissues and
induces apoptosis. The product of the arginase pathway, ornithine,
is acted upon by ornithine decarboxylase (ODC) to generate
ornithine. H. pylori–mediated apoptosis was blocked in the
presence of the host arginase inhibitor N-hydroxy-nor-L-arginine
(nor-NOHA), and also in the presence of an ODC inhibitor, a-
difluoromethylornithine (DFMO). iNOS inhibition had no effect
on H. pylori–mediated apoptosis. Arginase II induction was not
observed in mice infected with the nonpathogenic E. coli DH5a
strain [15]. This clearly demonstrates that the induction of host
arginase is directly correlated with the virulence of the organism.
However, there are no reports of arginase induction in hosts with
pathogenic E. coli, indicating the specific phenotype varies from
pathogen to pathogen. Further, E. coli lacks endogenous arginase.
Ornithine is converted to the polyamine spermidine by spermidine
synthase (Spd Syn). The next step of polyamine production
consists of the production of another polyamine spermine by
action of the spermine synthase (Spm Syn) enzyme (Figure 1). H.
pylori can utilize this spermine to restrain immune response in the
activated macrophages by inhibiting pro-inflammatory gene
expression. Spermine could also prevent the antimicrobial effects
of NO by inhibiting iNOS translation in the macrophages infected
by H. pylori [16]. Future work should provide insights into whether
the nor-NOHA-mediated host arginase inhibition can also
decrease H. pylori survival in human gastric tissues.
Another intracellular pathogen, Salmonella enterica serovar
Typhimurium, also utilizes the host arginase for its own survival
inside mouse macrophages. Salmonella is capable of causing clinical
signs that range from self-limiting diarrhea to severe fibrinopuru-
lent necrotizing enteritis and life-threatening systemic disease in
various hosts. In the spleen of Salmonella Typhimurium–infected
mice, a clear increase in the arginase II protein level and activity is
observed. Inhibition of arginase via nor-NOHA treatment leads to
increased NO production and decreased bacterial burden in the
secondary lymphoid organs of the infected mice. Arginase
induction is dependent on LPS or any other surface pathogen-
associated molecular pattern of Salmonella [17]. The factor that is of
importance here is the side effects of inhibition of the host urea
cycle. Further, the specific response of the human pathogen
Salmonella enterica serovar Typhimurium with respect to arginase
induction and modulation of the host arginine metabolism also
demands careful consideration.
The successful replication and survival of M. tuberculosis, the
causative agent of tuberculosis, inside host macrophages depends
on the intelligent strategies employed by the bacteria. In the case
of Mycobacterium bovis (BCG) infection, it has been demonstrated
that host urea production slowly increases with the infection time.
Figure 1. Overview of mammalian arginine metabolism. Only enzymes that directly use or produce arginine, ornithine, or citrulline are
identified, and not all reactants and products are shown. Inhibition of specific enzymes is indicated by H. DFMO, difluoromethyl ornithine; iNOS,
inducible nitric oxide synthase; NO, nitric oxide; nor-NOHA, nor-N
v-hydroxy-l-arginine; OAT, ornithine aminotransferase; ODC, ornithine
decarboxylase; PAMPs, pathogen-associated molecular patterns; Spd Syn, spermidine synthase; Spm Syn, spermine synthase.
doi:10.1371/journal.ppat.1000899.g001
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induction in J774.1 macrophage arginase activity. However, the
replication of intracellular BCG increased when arginase activity
was inhibited. Hence, it is indicative that the enhanced growth of
BCG might be due to increased availability of the intracellular
arginine pool to the bacteria in the arginase-blocked condition
[18].
In an interesting report, the exact mechanism of arginase
induction upon mycobacteria infection was documented. In
primary mouse macrophages, the BCG infection–mediated
increase in the arginase I protein was shown to be MyD88 and
TLR2 dependent and independent of the T helper type 2–
associated STAT6 pathway. Deletion of arginase I leads to an
enhanced NO response with BCG infection. Supporting the BCG
data, an increased arginase I mRNA expression was seen in the
lungs of M. tuberculosis–infected mice as well. A lower M. tuberculosis
load was observed in the Arg-1-deficient mice. In the same report
it was observed that the liver granuloma from BCG-infected mice
produced greater bacterial nitrotyrosine when host arginase was
knocked out [19]. The high NO in the Arg-1-deficient mice in
response to the M. tuberculosis infection in conjunction with
superoxide leads to the formation of the highly toxic peroxynitrite.
Bacterial nitrotyrosine is formed when peroxynitrite nitrosylates
tyrosine residues in bacteria. Although in the J774 macrophage
cell line arginase inhibition promoted BCG growth, in the mouse
model an opposite phenotype was observed. Arginase I–deficient
mice were more efficient at clearing both M. tuberculosis and BCG
by suppressing NO production from infected macrophages.
Recently, in another report it was observed that the supernatant
of BCG-infected wild-type macrophages induces arginase I in
MyD88
2/2 macrophages in a STAT3-dependent manner. This
induction was attributed to IL-6/IL-10 secretion by the BCG-
infected macrophages that induce arginase in neighboring
macrophages by autocrine/paracrine IL-6/IL-10 activation of
STAT3 [20]. It can be inferred from this that mycobacteria
condition uninfected neighboring cells for low NO production by
inducing arginase I.
Modulation of Arginase by Parasites
Trypanosoma cruzi is an obligate intracellular protozoan parasite
that grows abundantly in the heart and other organs of patients
with acute Chagas disease. Cruzipain (Cz), a major T. cruzi
antigen, was found to increase urea production in splenic
macrophages [21]. In a subsequent study, cardiocytes were
cultured with Cz and a significant increase in host arginase II
was observed. This enhanced arginase in turn promotes survival of
the mouse cardiomyocyte [22]. During in vivo infection of T. cruzi
in BALB/c mice, both arginase I and arginase II were induced in
heart tissues. On the one hand, this induction could provide
polyamine for the parasite’s growth, and on the other might also
downregulate the detrimental effects triggered by iNOS in the
heart during infection [23]. The reduced apoptosis rate of the
cardiomyocyte should ultimately generate an adequate environ-
ment for the parasite’s growth and dissemination from the host
heart. Hence, in T. cruzi infection, anti-apoptotic activity of
arginase and its downstream enzymes are utilized by the pathogen
for survival. We can speculate that NOHA-mediated arginase
inhibition might increase this apoptosis and consequently decrease
T. cruzi survival. This is in contrast to H. pylori infection, where
there is a host arginase II–dependent polyamine-mediated increase
in apoptosis, which might be explained by the differential cell and
tissue types wherein polyamine-mediated apoptosis is taking place.
Trypanosoma brucei causes trypanosomiasis in both humans and
animals in Africa. Both innate and adaptive immune responses of
the host are involved in resistance. Moreover, arginase is also
induced in T. brucei infection [24]. In the susceptible mouse strain
BALB/c, arginase I and II mRNA and arginase activity were
higher compared to the resistant mouse strain C57BL/6. Both of
these phenotypes were directly induced by T. brucei infection. In
accordance with this phenotype, NO production was significantly
higher in the C57BL/6 mice and must be the cause for their
resistance. Hence, the macrophage arginase inhibits NO-depen-
dent trypanosome killing. NO generation and parasite survival was
restored to the same level in both the susceptible and resistant
strains on arginase inhibition. Thus, here arginase serves as a host
marker for susceptibility to trypanosome infection [25]. Poly-
amines are further essential for trypanosome development, as they
help in the synthesis of DNA and trypanothione. In protozoans
such as Trypanosoma, polyamines like spermidine make trypa-
nothione, which is an antioxidant and is required for parasitic
proliferation [26,27]. NOHA treatment decreased parasitic
burden in the macrophage population [28]. This was achieved
by an increase in arginine availability for iNOS, and it has been
observed that supplementation of arginine restores NO-dependent
parasite killing. At this point, the use of the T. brucei–mediated
arginase pathway has been identified, but how the pathogen elicits
arginase remains ambiguous.
Curiously, T. brucei does not use the arginase pathway for its
spread like T. cruzi. This contrast might be explained by the fact
that in the case of T. cruzi infection, apoptosis of the infected heart
tissue cells is very much required for the pathogen to invade other
organs, which is not the case for T. brucei, as it can spread via
infected macrophages in the peritoneum cavity. Further investi-
gation is required to determine the effect of arginase at the
systemic level during experimental trypanosomiasis.
The protozoan Leishmania is an intracellular parasite of
mammalian macrophages. To reside successfully in the very cells
responsible for its clearance, Leishmania requires a bag full of
immune evasion tricks. This involves avoidance of phagolysosomal
fusion and prevention of activation of acquired immune
mechanisms. Macrophages can control Leishmania infection when
a T helper Type 1 response is mounted and pro-inflammatory
cytokines like IFNc and TNF-a are released. This leads to the
induction of iNOS and NO production, which is the major
Leishmania killer molecule in the murine system. Arginine, the
substrate of NO production, is modulated by both Type 1 and
Type 2 responses in a manner such that the Type 1 response
increases IFNc-induced iNOS-mediated conversion of arginine to
NO, whereas the Type 2 response promotes arginase induction.
[29].
High splenic arginase I expression has been documented in the
hamster model of progressive visceral leishmaniasis caused by
Leishmania donovani [30]. Further, in subsequent studies, it was
shown that even L. major infection leads to arginase I induction in
macrophages, and that host arginase I induction supports
Leishmania growth. Host arginase I is induced in both the resistant
C57BL/6 and susceptible BALB/c mouse strains. However, in
C57BL/6 mice, it is induced only during foot pad swelling, and in
BALB/c it parallels time of infection. Specific inhibition of host
arginase I by nor-NOHA treatment decreases the parasite load
and delays lesion development in susceptible BALB/c mice. On
the other hand, in resistant C57BL/6 mice ornithine supplemen-
tation increases the susceptibility of infection, clearly suggesting
that in cutaneous leishmaniasis the host arginase pathway is
hijacked by the parasite for polyamine acquisition [31]. L. major
increases host arginase I for enhanced polyamine production,
which acts as a growth factor. Further, spermidine and spermine
inhibit the pro-inflammatory cytokine response of the host, and
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TLR4 pathway. The inhibition of host arginase I activity has the
therapeutic effect of reduced pathology and controlled L. major
replication by decreasing polyamine synthesis [32].
Further, it has also been reported that the inhibition of L. major–
encoded arginase controls parasite growth. This growth inhibition
is caused by decreasing ornithine availability for polyamine
synthesis and not by decreasing the host NO response. It was
also observed that increasing parasite arginase activity by IL-4
induction further promotes Leishmania growth [33]. It interesting to
note here that simultaneous inhibition of both the L. major–
encoded arginase and the host arginase I did not result in an
increase in the nitrite levels or in the Type 1 immune response of
the host [32,33]. Polyamine biosynthesis in Leishmania occurs by
the arginase-ODC pathway only. Consequently, Darg L. major are
auxotrophic for polyamines. However, L. major lacking arginase
retains infectivity in the susceptible BALB/c mouse strain. This
clearly indicates that arginase-deficient Leishmania can survive in
mice by salvaging the polyamines synthesized by the host.
However, the pathology in the Darg L. major infection emerged
less rapidly than in the wild-type infection. [34].
Strikingly, the active role played by Leishmania arginase in
diverting arginine away from the iNOS pathway was demonstrat-
ed by the increased host NO response to Darg Leishmania mexicana
infection in mice. The Darg L. mexicana infection led to an
enhanced Type 1–associated IFNc response as well. This led to a
significant growth attenuation of Darg L. mexicana in mice [35].
This difference in survival between L. major and L. mexicana
arginase knockouts can be attributed to the varied roles played by
parasite-encoded arginase in the pathogenesis of different
Leishmania species. There is also the possibility of the existence of
an alternate arginase of L. major. Further, L. major might have an
enhanced capacity to acquire host polyamines to support its
growth in mice.
Host NO response is essential also in the control of Toxoplasma
gondii infection [36,37]. To circumvent this NO-mediated killing,
T. gondii induces host arginase I protein expression in a STAT6-
independent manner within 1 hour of infection. In accordance
with the induction, mice lacking arginase I showed a survival
advantage over control mice during experimental toxoplasmosis.
Mice lacking arginase I did not lose weight and did not show any
sign of toxoplasmosis, unlike the control mice [19]. Although the
chief mechanism for host survival in T. gondii infection is attributed
to a decrease in NO production, there might be additional
functions of arginase in Toxoplasma infection.
Arginase is further involved in the pathogenesis of Schistosoma
mansoni. It regulates the granulomatous pathology of schistosomi-
asis in vivo. In infected lung tissues, arginase activity is induced by
scistosome eggs. Most of the arginase activity was derived from the
host arginase I isoforms as observed by both RNA and protein
data [38]. Mice carrying S. mansoni infection further showed a
heightened arginase I expression in resident peritoneal macro-
phages. In the same study, a 10-fold higher level of circulating
ornithine-derived polyamines were found in infected mice when
compared to the control group [39]. This is of pathological
significance as parasitic helminthes are known to depend on their
host for uptake and interconversion of polyamines. The effect of
arginase inhibition has not been tested on S. mansoni growth.
However, an inhibition of the ODC enzyme by DFMO
administered in drinking water after 5 weeks post-infection
increases granuloma size and hepatic fibrosis in mice. This is
explained by the enhanced bioavailability of L-ornithine in the
absence of ODC towards ornithine amino transferase (OAT) for
proline synthesis. Hence, it can be indirectly concluded from here
that Schistosoma-mediated arginase I induction helps the parasite by
increasing the available proline for increased collagen deposition
[38]. However, direct proof can be obtained only after the
development of a specific OAT inhibitor. In Schistosoma-infected
livers, proteomic study shows that the overall abundance of
arginase I protein is equal to that observed in uninfected livers.
This data is consistent with various previous findings wherein
arginase I is increased in the granuloma but not in the
parenchyma [40].
Schistosoma S. mansoni expresses its own endogenous arginase as
well. Although there are structural differences between the host
and Schistosoma arginase, they are both functionally similar.
Arginase activity increases in case of Schistosoma invasion of the
host skin, and this increase is directly attributable to the Schistosoma
endogenous arginase. It is probable that Schistosoma attempts to
control toxic NO production by the resident innate immune cells
in the skin through arginase. However, the exact role of the
parasite arginase in Schistosoma pathogenesis has to be further
elucidated [41].
Survival Advantage Conferred by Arginase to Other
Pathogens
The opportunistic fungal pathogen Candida albicans is part of the
normal microflora but can cause systemic infection in immune-
compromised individuals when it reaches the bloodstream. In
order to escape from macrophages after being ingested, Candida
employs a very fascinating strategy of inducing its own
intracellular arginase (Car1p) and urea amidolyase to achieve
hyphal switching. Once inside the macrophages, Candida rapidly
upregulates its arginine biosynthetic genes. Arginine is further
metabolized to ornithine and urea by arginase. The resulting urea
is degraded to CO2 and NH3 by urea amidolyase (Dur1, 2p). CO2
further activates adenyl cyclase and the cAMP-dependent protein
kinase A pathway, thereby activating Efg1p, which triggers the
yeast-to-hypha switch of Candida inside macrophages, enabling its
release. In addition, Candida induces two other endogenous
arginases that are secreted out. These extracellular arginases
may provide a survival benefit to Candida by reducing nitrosative
stress via quenching the iNOS substrate arginine [42].
It is further reported that in hepatitis C virus (HCV) infection,
arginase I mRNA and protein expression is elevated. siRNA-
mediated inhibition of arginase I leads to the inability of HCV to
stimulate hepatocellular growth. Arginase inhibition also increased
NO-mediated cell death. Hence, arginase I plays a very significant
role in HCV-mediated hepatocellular growth and survival [43].
Spatial Localization of Arginases
Mammalian arginase I has a cytoplasmic localization, whereas
mammalian arginase II is present in the mitochondrial matrix [2].
These two arginases can access the cytoplasmic arginine pool and
modulate iNOS function by means of substrate quenching.
However, this brings us to an intriguing question about how
pathogenic arginases that are intracellular and not secreted outside
the cytosol can get access to the host arginine pool. It is well
documented that Schistosoma arginase is localized to the head of the
organism and is not secreted upon infection [41], nor is the H.
pylori arginase, which is again intracellular [44], or the Leishmania
arginase, which contains a peroxisomal targeting signal (PTS-1)
that directs it to the glycosome, an organelle unique to Leishmania
that again is not secreted out [45]. The answer would probably lie
in the unique ability of the pathogens to recruit the host arginine
transporters to their vacuoles to access the cytoplasmic pool and
also to utilize their own endogenous arginine uptake systems. It is
hypothesized for Leishmania that it recruits host mCAT2B
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further reported that the L. donovani promastigote uses its own
arginine permease, LdAAP3, to transport arginine across its
membrane [46]. Mycobacteria infection also upregulates host
arginine transport and utilizes this host-derived amino acid for its
own benefit instead of synthesizing its own [18]. Helicobacter is
known to possess its own arginine transport protein, RocE, to
uptake arginine present in the extracellular milieu [44]. Further,
the recruitment of the host arginine transporter mCAT1 to
Salmonella–containing vacuoles and involvement of ArgT, the
arginine permease of Salmonella in arginine uptake from host
cytosol, has also been observed (unpublished data, P. Das, A.
Lahiri, Ay. Lahiri, D. Chakravortty, et al.). Pathogens employ this
clever strategy of channeling the host arginine pool to the
intracellular pathogen-containing vacuole, and then uptake by its
own arginine transporters inside the cytosol of the pathogen. Thus,
pathogen-encoded arginases can modulate iNOS activity irrespec-
tive of their spatial localization by modulating the cellular
distribution of arginine.
Taken together, it is evident that several intracellular pathogens,
such as H. pylori, Salmonella Typhimurium, and M. tuberculosis,
survive nitrosative stress by inducing the counteractive enzyme of
iNOS, arginase, inside the host macrophages. Arginase promotes
Toxoplasma and HCV infection as well by providing protection
from host-induced NO stress. However, it is interesting to note
that in the case of intracellular survival of parasites like
Trypanosoma, Leishmania, and Schistosoma, arginase offers a survival
advantage mainly by a polyamine-dependent and NO-indepen-
dent mechanism. Arginase comes into play even in the
establishment of fungal infections. Candida escape from host
macrophages is mediated by arginase induction. Thus, arginase
induction is clearly a very widespread and essential response in
pathogenic infections.
Therapeutic Implications
Targeting arginase and the polyamine biosynthetic pathways is
being attempted nowadays in various diseases such as African
sleeping sickness, Chagas disease, and leishmaniasis [47]. Arginase
inhibition has high therapeutic value in disorders due to impaired
NO production like psoriasis, septic shock, vascular diseases,
airway hyper responsiveness, and rheumatoid arthritis.
Arginase isoforms regulate the availability of proline for cell
proliferation and collagen deposition during diseases such as
asthma and cancer. In these cases disease progression can be
delayed by inhibiting arginase by nor-NOHA [48]. Although most
of the work cited here deals with the mouse system, let us now
consider the cases where arginase function has been targeted for
therapeutic application in humans. It has been observed recently
that HCV induces arginase expression in liver carcinoma, and
arginase I–specific siRNA inhibited the ability of the virus to
stimulate hepatocellular growth [43]. In addition, inhibition of
ODC by the irreversible ODC inhibitor DFMO and the specific
inhibition of spermidine biosynthesis by cyclohexylamine are
Figure 2. Modulation of arginase by various pathogens.
doi:10.1371/journal.ppat.1000899.g002
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treatment of human leishmaniasis and sleeping sickness, poly-
amine synthesis inhibitors have been proved to be useful. Now that
we know that arginase is a crucial factor for the survival of human
pathogens, investigators can look more closely for new and specific
inhibitors of arginase.
It has been further observed that in Leishmania infection in young
mice, the parasite burden was higher than in the aged mice [51].
When the underlying mechanism was addressed, it was found that
the young mice actually express a higher level of arginase than the
older mice group, and this age-related alteration of arginase
impacts the severity of Leishmania pathogenesis. Thus, studies in
this line to understand the age-related expression of arginase in
humans should be conducted prior to targeting the arginase
pathway or arginine metabolism during disease.
Pathogens have evolved different strategies to escape immune
responses, especially by taking advantage of the host defense
mechanisms developed to cope with the invading pathogen. Here,
in this review, we have summarized how a metabolic enzyme used
for urea production and involved in nitrogen metabolism is
hijacked by various pathogens towards their own survival.
Modulation of the arginase pathway leads to decreased bacteri-
cidal NO production, increased or decreased apoptosis, and
increased polyamine or proline synthesis. Each of the organisms
that we discussed tries to downregulate host NO production, but
the various other effects that are achieved by modulating arginase
function is pathogen specific. It is tempting to propose that these
effects might be used to subvert normal host cellular functions that
are needed to counteract the pathogenic insult.
It should be kept in mind that arginase induction benefits the
host by reducing the detrimental effect of NO and supplying
polyamines for cell proliferation and proline for collagen
deposition. Further, the urea cycle is an essential biochemical
pathway in the host needed to clear the toxic waste product
ammonia. Arginase also potentially regulates arginine-dependent
immune functions such as T lymphocyte activation. Thus, any
approach to treat pathogenic diseases by host arginase inhibition
should be addressed with considerable caution.
Conclusions
Thus, the critical interplay between the host and the pathogen
to regulate arginase isoforms could determine the outcome of
several infections. For example, Staphylococcus aureus is a pathogen
carrying its own arginase and might modulate host arginase [52].
This pathway might be one of the important mechanisms of
Staphylococcus to avoid host immune response and remains to be
validated. Although considerable data have been generated in
studies of the ten pathogens described in this review (Figure 2 and
Table 1), many questions still remain. One of the important
questions that remain to be answered is whether the pathogen
gains by utilizing host arginase. How much physiological
significance does this modulation have? How effective will arginase
inhibition prove in any disease in human? What are the moieties of
the pathogen that actually lead to arginase modulation? Taken
together, arginase in pathogenesis will be a fruitful avenue of
further research and will stimulate further research on both
arginine metabolism and arginase function in the context of
pathogenesis.
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